1
|
Fonta CM, Arnoldini S, Jaramillo D, Moscaroli A, Oxenius A, Behe M, Vogel V. Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes. Matrix Biol Plus 2020; 8:100046. [PMID: 33543039 PMCID: PMC7852196 DOI: 10.1016/j.mbplus.2020.100046] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 07/09/2020] [Accepted: 07/09/2020] [Indexed: 12/12/2022] Open
Abstract
The extracellular matrix (ECM) acts as reservoir for a plethora of growth factors and cytokines some of which are hypothesized to be regulated by ECM fiber tension. Yet, ECM fiber tension has never been mapped in healthy versus diseased organs. Using our recently developed tension nanoprobe derived from the bacterial adhesin FnBPA5, which preferentially binds to structurally relaxed fibronectin fibers, we discovered here that fibronectin fibers are kept under high tension in selected healthy mouse organs. In contrast, tumor tissues and virus-infected lymph nodes exhibited a significantly higher content of relaxed or proteolytically cleaved fibronectin fibers. This demonstrates for the first time that the tension of ECM fibers is significantly reduced upon pathological tissue transformations. This has wide implications, as the active stretching of fibronectin fibers adjusts critical cellular niche parameters and thereby tunes the reciprocal cell-ECM crosstalk. Mapping the tensional state of fibronectin fibers opens novel and unexpected diagnostic opportunities. Mechanobiology of extracellular matrix changes upon pathological transformations. Fibronectin is significantly more relaxed in tumors than in healthy organs. Relaxed fibronectin is found close to myofibroblasts and dense collagen fibers. Viral infection reduces fibronectin fiber tension in lymph nodes. Use of a tension-sensitive adhesin to probe fibronectin fiber tension in tissues
Collapse
Key Words
- CAFs, cancer associated fibroblasts
- CLEC-2, C-type Lectin Receptor
- Cancer
- DCs, dendritic cells
- ECM, extracellular matrix
- Extracellular matrix
- FRCs, fibroblastic reticular cells
- Fibronectin
- IHC, immunohistochemistry
- IL-7, Interleukin 7
- LCMV, lymphocytic choriomeningitis virus
- Lymph node
- MMPs, matrix metalloproteinases
- Mechanobiology
- PDPN, podoplanin
- SHG, second harmonic generation
- TGF-β, Transforming Growth Factor-beta
- Virus infection
- α-SMA, alpha smooth muscle actin
Collapse
Affiliation(s)
- Charlotte M Fonta
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, CH-8093 Zurich, Switzerland
| | - Simon Arnoldini
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, CH-8093 Zurich, Switzerland
| | | | - Alessandra Moscaroli
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, CH-5232 Villigen, Switzerland
| | - Annette Oxenius
- Institute of Microbiology, ETH Zürich, CH-8093 Zurich, Switzerland
| | - Martin Behe
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, CH-5232 Villigen, Switzerland
| | - Viola Vogel
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, CH-8093 Zurich, Switzerland
| |
Collapse
|
2
|
Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes Obes Metab 2018; 20:1921-1927. [PMID: 29652101 DOI: 10.1111/dom.13318] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 03/23/2018] [Accepted: 04/03/2018] [Indexed: 10/17/2022]
Abstract
AIMS The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant improvements in glycated haemoglobin (HbA1C) and body mass index (BMI). Based on these findings, the aim of the present study was to assess the long-term cost-effectiveness of switching from sitagliptin to liraglutide in patients with type 2 diabetes in the UK. MATERIALS AND METHODS The IQVIA CORE Diabetes Model Version 8.5+ was used to project costs and clinical outcomes over patients' lifetimes. Baseline cohort characteristics and treatment effects were derived from the LIRA-SWITCH trial. Future costs and clinical benefits were discounted at 3.5% annually. Costs were accounted in pounds sterling (GBP) and expressed in 2016 values. One-way and probabilistic sensitivity analyses were performed. RESULTS Model projections showed improved quality-adjusted life expectancy for patients with poorly controlled HbA1c upon switching from sitagliptin to liraglutide, compared with continuing sitagliptin treatment (9.18 vs 9.02 quality-adjusted life years [QALYs]). Treatment switching was associated with increased overall costs (GBP 24737 vs GBP 22362). Higher pharmacy costs were partially offset by reduced diabetes-related complication costs in patients who switched to liraglutide. Switching to liraglutide was associated with an incremental cost-effectiveness ratio of GBP 15423 per QALY gained vs continuing with sitagliptin treatment. CONCLUSIONS Switching from sitagliptin 100 mg to liraglutide 1.8 mg in patients with poor glycaemic control was projected to improve clinical outcomes and is likely to be considered cost-effective in the UK setting and, therefore, a good use of limited NHS resources.
Collapse
Affiliation(s)
- Anthony H Barnett
- Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Simon Arnoldini
- Ossian Health Economics and Communications, Basel, Switzerland
| | - Barnaby Hunt
- Ossian Health Economics and Communications, Basel, Switzerland
| | | | | |
Collapse
|
3
|
Arnoldini S, Moscaroli A, Chabria M, Hilbert M, Hertig S, Schibli R, Béhé M, Vogel V. Novel peptide probes to assess the tensional state of fibronectin fibers in cancer. Nat Commun 2017; 8:1793. [PMID: 29176724 PMCID: PMC5702617 DOI: 10.1038/s41467-017-01846-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 10/19/2017] [Indexed: 01/16/2023] Open
Abstract
Transformations of extracellular matrix (ECM) accompany pathological tissue changes, yet how cell-ECM crosstalk drives these processes remains unknown as adequate tools to probe forces or mechanical strains in tissues are lacking. Here, we introduce a new nanoprobe to assess the mechanical strain of fibronectin (Fn) fibers in tissue, based on the bacterial Fn-binding peptide FnBPA5. FnBPA5 exhibits nM binding affinity to relaxed, but not stretched Fn fibers and is shown to exhibit strain-sensitive ECM binding in cell culture in a comparison with an established Fn-FRET probe. Staining of tumor tissue cryosections shows large regions of relaxed Fn fibers and injection of radiolabeled 111In-FnBPA5 in a prostate cancer mouse model reveals specific accumulation of 111In-FnBPA5 in tumor with prolonged retention compared to other organs. The herein presented approach enables to investigate how Fn fiber strain at the tissue level impacts cell signaling and pathological progression in different diseases.
Collapse
Affiliation(s)
- Simon Arnoldini
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland
| | - Alessandra Moscaroli
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, OIPA/103, 5232, Villigen PSI, Switzerland
| | - Mamta Chabria
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland
| | - Manuel Hilbert
- Laboratory of Biomolecular Research, Paul Scherrer Institute, OFLC/102, 5232, Villigen PSI, Switzerland
| | - Samuel Hertig
- Hertig Visualizations, Technikumstrasse 10B, 3400, Burgdorf, Switzerland
| | - Roger Schibli
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, OIPA/103, 5232, Villigen PSI, Switzerland.,Institute for Pharamaceutical Science, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland
| | - Martin Béhé
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, OIPA/103, 5232, Villigen PSI, Switzerland.
| | - Viola Vogel
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland.
| |
Collapse
|